Travere Therapeutics

We’re in Los Angeles for the ACMG - American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting #ACMGMtg25 where we look forward to sharing our research in classical #homocystinuria (HCU). Dr. Can Ficicioglu, clinical director of the Metabolic Disease Program at the Children's Hospital of Philadelphia, will give a poster presentation this Thursday highlighting results of the ACAPPELLA Study, our natural history study in classical HCU to gain greater understanding of disease progression in this challenging metabolic condition. At Travere, we are working to bring new hope to the classical HCU community. #InRareForLife

Today we announced that we have submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). Press release: https://bit.ly/3FMfqFx #InRareForLife

“Pushing for progress simply, and heartbreakingly, requires that more people understand just how tough living with rare kidney disease is.” As she reflects on World Kidney Day and a recent visit from Jen, living with FSGS, our chief medical officer Jula Inrig shares the importance of research and innovation for the RKD community. #AreYourKidneysOK? #RareKidneyDisease #InRareForLife

Today is #WorldKidneyDay! This year's theme, #AreYourKidneysOK?, raises awareness of the importance of early detection of kidney disease. At Travere, we strive to make a positive impact on the lives of people living with #RareKidneyDisease. To learn more about kidney health, visit https://lnkd.in/fW-T8xB. #InRareForLife

At 26 years old, Kate has lived with IgA nephropathy, a #RareKidneyDisease (RKD), for 6 years. A proper diagnosis didn’t come easily; she developed high blood pressure and swelling in her calves and feet, to the point of not being able to fit in her shoes. Kate still has symptoms and is actively fighting the disease with the help of her nephrologist whom she trusts. “Just because my life looks different after diagnosis doesn’t mean that I still can’t have a good life,” Kate says. This #NationalKidneyMonth, learn more about Kate’s story: travere.com/rare-life/kate #InRareForLife #RKDandMe

Today is #NationalEmployeeAppreciationDay and #HereAtTravere our team members are enjoying a well-deserved wellness day! Whether it is spent enjoying some time on the beach with friends or recharging at home, we encourage our teams to disconnect and refocus for the great year ahead. We also want to take a moment to thank our team members on this special day and share how proud we are to continue to work together to identify, develop and deliver life-changing therapies to people living with rare disease. #TravereTherapeutics #InRareForLife

“Breathe, just breathe,” Kim says, in encouragement to her younger self when she was first diagnosed with #IgAnephropathy. Diagnosed at 23, Kim felt blindsided by her #IgAN diagnosis, and frightened about her future. But today she feels hope because of the progress being made in #RareKidneyDisease research. This #NationalKidneyMonth, check out Kim’s story. #InRareForLife #RKDandMe

We’re published! Our clinical and pre-clinical research in rare nephrology and metabolic disease has recently come out in some distinguished peer-reviewed journals. Check out our newest titles here: https://lnkd.in/gyUdD-3M #InRareForLife

At Travere, we believe that every rare disease journey is unique—when you hear one patient’s story, you hear just that: one story. Understanding each experience is integral to healthcare and drug development. During our #RareDiseaseDay discussion today, panelists shared their insights, resilience, and the power of speaking up: "The first place you have to use your voice is for yourself as a patient." – Tiffany "Be loud. If something feels wrong, make a ruckus until you are heard." – Gabrielle “It’s amazing how much you can learn from other patients—our shared experiences make us stronger." – Sean "We must make sure that patients aren’t just part of the conversation, but at the center of every decision." – LaVarne Burton, president & CEO of American Kidney Fund Their stories remind us that there is no one-size-fits-all approach to rare disease care. Every patient’s needs and challenges are different, and true patient centricity means listening to them all. This Rare Disease Day, and every day, we are focused on amplifying every voice and ensuring that each patient’s unique story shapes the future of rare disease care. #InRareForLife #ShowYourStripes

In this #RareDiseaseDay2025 message, our president and CEO, Eric Dube, shares the importance of listening to patient voices and understanding their journeys in order to better guide the work we do for rare disease patients. #InRareforLife